Table 5 Main differences between the groups of patients that reduce and those that increase the plasma concentration of NETs byproducts after sleeve gastrectomy.
From: Increased plasmatic NETs by-products in patients in severe obesity
Patients that reduce MPO-DNA concentration after sleeve gastrectomy | Patients that increase MPO-DNA concentration after sleeve gastrectomy | P | |
|---|---|---|---|
N | 40 | 33 | |
MPO-DNA complexes before treatment (OD) | 0.5 ± 0.13 | 0.42 ± 0.18 | <0.05 |
MPO-DNA complexes after treatment (OD) | 0.36 ± 0.14 | 0.66 ± 0.27 | <0.001 |
MPO-DNA ratio (before/after) | 1.63 ± 1.3 | 0.67 ± 0.22 | <0.001 |
Age median yrs (range) | 43.6 ± 11 | 43.6 ± 12.5 | 0.929 |
Males/females (n) | 13/27 | 11/22 | 0.940 |
Smoke (n) | 10 | 9 | 0.928 |
Diabetes mellitus (n) | 4 | 5 | 0.505 |
Coronary heart disease (n) | 1 | 2 | 0.446 |
Stroke (n) | 0 | 2 | 0.114 |
History of thromboembolic events (n) | 0 | 4 | <0.05 |
Hypertension (n) | 15 | 12 | 0.92 |
Hypercholesterolemia (n) | 0 | 1 | 0.653 |
Thyroid disease (n) | 6 | 5 | 0.516 |
COPD (n) | 2 | 1 | 0.673 |
Body mass index variation (before-after, Kg/m2) | 11.8 ± 5.1 | 11.2 ± 3.5 | 0.678 |
Weight variation (before-after, kg) | 31.7 ± 13.8 | 29.9 ± 15.3 | 0.670 |
Subcutaneous fat variation (before-after, mm) | 12.8 ± 9.3 | 8.3 ± 6.6 | 0.056 |
Triglycerides variation (before-after, mg/dL) | 46.0 ± 72.51 | 35.7 ± 68.2 | 0.878 |
